Clik here to view.
Lonnel Coats announces retirement from Lexicon; Another shakeup in Vir's C-suite
Lonnel Coats → Lexicon Pharmaceuticals CEO Lonnel Coats will retire July 7, 10 years to the day after accepting the job. Lexicon overcame numerous regulatory obstacles with its SGLT1/2 inhibitor...
View ArticleBipartisan draft bill would pay hospitals more to combat drug shortages
The Senate Finance Committee released a new bipartisan draft legislation on Friday morning that would incentivize generic manufacturers and healthcare providers, like hospitals and clinics, to mitigate...
View ArticleClik here to view.
AEON fails another migraine trial, shares halve as company reviews options
AEON Biopharma said its botulinum toxin treatment candidate failed a Phase 2 migraine study at the planned interim analysis. The company’s share price $AEON was halved in premarket trading on Friday....
View ArticleRoyalty Pharma's milestone payment to Arrowhead; Abeona's $75M offering
Plus, news about Soleno, Novo Nordisk and Cardior Pharmaceuticals: Royalty Pharma pays Arrowhead Pharmaceuticals: The $50 million milestone payment comes after the completed enrollment of a Phase 3...
View ArticleRo CEO Zachariah Reitano talks GLP-1 drug pricing, shortages and compounded...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The fight to dominate the market for weight loss shots has never been hotter, but drugmakers still can’t...
View ArticleClik here to view.
CG Oncology touts interim Phase 3 bladder cancer data as it gears up to...
An experimental oncolytic virus therapy developed by CG Oncology helped clear tumors in 75% of bladder cancer patients in a Phase 3 study. The therapy, known as cretostimogene grenadenorepvec, or creto...
View ArticleFTC wants more information on Novo-Catalent deal in antitrust review
The Federal Trade Commission has extended its antitrust review of Novo Holdings’ $16.5 billion purchase of Catalent by potentially another 30 days as it requests additional information. Both the...
View ArticleHouse to mark up bill targeting Chinese biotech and genomics companies
The House Oversight Committee will mark up a far-reaching bill on May 15 that, if passed, could force many US biopharma companies to cut ties with WuXi and several other Chinese life sciences...
View ArticleClik here to view.
AbbVie puts $161M into new R&D site in Germany, will add 300 jobs
AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week. At a...
View ArticleClik here to view.
Senators from both parties introduce menopause research bill
A group of Democratic and Republican senators introduced a bill on Thursday that calls for $275 million toward federal menopause research and awareness efforts over five years. The legislation would...
View ArticleJ&J showcases more bladder cancer results from 'pretzel' drug-device combo
Updated data from a trial of Johnson & Johnson’s experimental “pretzel” showed that more than 80% of bladder cancer patients who got the treatment saw their tumors melt away, building on a readout...
View ArticleNovartis’ radiopharma gambit; Weight loss battle plays out; Spark...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticlePfizer hires Citi analyst Andrew Baum to oversee portfolio strategy
Pfizer has tapped Wall Street analyst Andrew Baum to be its new chief strategy and innovation officer, where he’ll head up management of the company’s portfolio and work on partnerships. Baum has been...
View ArticleClik here to view.
OverT Bio debuts with $16M to find new ways to make solid cancer cell therapies
A new biotech is coming out of stealth with $16 million to develop cell therapies for solid cancers — an area where scientists have had limited success. OverT Bio (pronounced “overt,” not “over-T”)...
View ArticleAstraZeneca expands stake in cell and gene therapy partner Cellectis
UK pharma giant AstraZeneca on Monday unveiled another $140 million equity investment in cell and gene therapy partner Cellectis. AstraZeneca now owns 44% of Cellectis’ share capital and has 30% of the...
View ArticleClik here to view.
GlycoMimetics stock tumbles after Phase 3 trial fail in AML
GlycoMimetics’ stock $GLYC tanked over 60% in premarket trading Monday morning after the biotech announced a Phase 3 trial failure for its lead drug, uproleselan, in relapsed/refractory acute myeloid...
View ArticleGossamer Bio collaborates with Chiesi to develop, commercialize seralutinib
Gossamer Bio has lined up a partner to foot the development and commercialization bill for its make-or-break late-stage drug, expanding Phase 3 plans and paving the way for its launch outside the US....
View ArticleClik here to view.
AstraZeneca-allied Eccogene targets early 2025 Nasdaq IPO with multiple NASH...
Eccogene, a Boston and Shanghai biotech working on an oral GLP-1 candidate with AstraZeneca, is considering an initial public offering early next year, CEO Jingye Zhou told Endpoints News. Jingye Zhou...
View ArticleGates, Novo Nordisk, Wellcome foundations put $300M in global health;...
Plus, news about EyePoint, Lyra Therapeutics and Plus Therapeutics: For global health, $300 million: The Bill & Melinda Gates Foundation, the Novo Nordisk Foundation and Wellcome are each pitching...
View ArticleJ&J reports latest data on Balversa ‘pretzel’ therapy for bladder cancer
Bladder cancer patients with a common mutation saw promising early results after receiving a Johnson & Johnson targeted therapy called Balversa that’s administered through a slow-releasing...
View Article